Never pay monthly for cloud storage again with this 2TB lifetime deal
The following content is brought to you by Mashable partners. If you buy a product featured here, we may earn an affiliate commission or other compensation.
TL;DR: Score 2TB of cloud storage for life with this deal from FileJump Cloud Storage, now just $69.97 (reg. $467) through July 20.
Ever feel like your phone is a digital junk drawer filled with photos, videos, and files you keep meaning to organize? Whether you're the go-to family photographer or juggling work files for your side hustle, it's time to find a permanent space for your data.
FileJump Cloud Storage provides 2TB of lifetime cloud storage for just $69.97 — no monthly fees, no catches — but you need to act fast. This deal only runs through July 20.
Ditch the monthly cloud storage fees with this lifetime plan from FileJump
Whether you're ready to stop spending a fortune on monthly cloud storage fees or finally take the initiative to safeguard your files in the cloud, let FileJump help. You can securely save files of all formats — from images and videos to MS Excel files — with this handy service, making it ideal for both personal and professional use.
Uploading is easy with FileJump's drag-and-drop interface. Simply drop them into your FileJump dashboard and relax knowing they're securely stored. You can then access them at any time, from anywhere.
FileJump offers built-in preview support so you can check out your content without having to download it. Speaking of downloading, you'll enjoy unlimited downloads and no speed caps for a seamless experience. Need to share something? That's easy too, with the option to share files or folders using secure links.
This lifetime subscription with 2TB of storage is only available to new FileJump users, who will enjoy the ample storage, unlimited downloads, and 15GB per file upload.
Keep your important files safe with this lifetime subscription to FileJump Cloud Storage, now only $69.97 (reg. $467) until July 20.
StackSocial prices subject to change.
Opens in a new window
Credit: FileJump
FileJump 2TB Cloud Storage: Lifetime Subscription
$69.97 $467 Save $397.03
Get Deal
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Eli Lilly (NYSE:LLY) Faces $7 Billion Lawsuit While Partnering With Innovative Biotech
Eli Lilly has been in the spotlight recently with a 3.96% share price increase over the past month. The selection of RyboDyn Inc. to join Lilly Gateway Labs stands out among recent developments, signaling strengthened research capabilities in precision immunotherapies and potentially bolstering investor confidence. Additionally, the company's legal entanglement with the lawsuit concerning Actos, following a class certification affirmation, highlights ongoing challenges in the pharmaceutical sector. The company's ongoing talks to acquire Verve Therapeutics also show its commitment to growing its gene-editing capabilities. These events have added weight to the broader market's trends. We've identified 2 warning signs for Eli Lilly (1 can't be ignored) that you should be aware of. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Recent developments at Eli Lilly, such as the RyboDyn Inc. collaboration, have potential implications for its strategic growth, particularly in precision immunotherapies. This aligns with the company's narrative of expanding capabilities in oncology and immunology, indicating possible enhancements in revenue and earnings forecasts over the long term. Additionally, as Eli Lilly progresses with Phase III trials, including those for orforglipron, the anticipated product approvals could bolster revenue avenues by tapping into high-demand markets like diabetes and obesity treatments. Over the past five years, Eli Lilly's total shareholder return was a very large 430.14%, demonstrating substantial long-term growth despite recent underperformance against the US Pharmaceuticals industry, which saw a 8.9% drop over the past year. This impressive five-year return provides context to the company's current position, underscoring a history of robust shareholder value creation. Given the ongoing acquisition talks with Verve Therapeutics and Eli Lilly's significant investment in both manufacturing and R&D, the outlook for future revenue and earnings remains optimistic. However, potential regulatory hurdles and pricing pressures, particularly in the U.S. market, highlight possible challenges. The shares, with a current price of US$775.12, are 21.0% below the analyst consensus target of US$981.63. This discount suggests room for growth, should the company meet or exceed the analyst expectations on revenue and earnings. Learn about Eli Lilly's future growth trajectory here. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:LLY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
39 minutes ago
- Yahoo
Stellantis Evaluates Maserati's Future, Including Potential Sale -- Reuters
Stellantis (STLA, Financials) is weighing a possible sale of its luxury brand Maserati as part of a broader strategic review, according to a Reuters report citing two unnamed sources familiar with the matter. Warning! GuruFocus has detected 11 Warning Signs with STLA. The discussions reportedly began before newly appointed CEO Antonio Filosa officially takes the helm. Maserati's future is under review as Stellantis navigates a shrinking U.S. market, Chinese competition, and steep tariffs imposed by President Donald Trump on foreign-made cars and parts. Despite the internal review, a Stellantis spokesperson told Reuters that Maserati is not for sale. McKinsey declined to comment. Maserati's sales fell by over 50% last year to 11,300 units, with no new models currently scheduled for launch. A new business plan is expected once Filosa begins his tenure. Stellantis' board remains split on the brand's futuresome directors reportedly view Maserati as a reputational asset, while others believe it lacks viability for a sustainable relaunch. Analysts say streamlining Stellantis' 14-brand portfolio could improve profit margins. The company's shares have lost roughly two-thirds of their value since March 2024. Chinese automakers such as Chery could emerge as potential buyers, echoing earlier moves like Geely's acquisition of Volvo or SAIC's purchase of MG. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
How Advisors Can Avoid Becoming Over-Reliant on AI
Apparently there's no AI in team. Artificial intelligence is being hailed as a key element of the fourth industrial revolution, and new tools are now assisting financial advisors with taking notes, drafting emails, and brainstorming thought leadership content. In fact, the vast majority of advisors said generative AI helped their practices, according to a survey earlier this year. But AI isn't a silver bullet. It lacks emotional intelligence and a human touch. Advisors risk damaging client relationships if they become too reliant on automation — even for routine tasks. 'AI is poor at empathy so far,' said Adrian Johnstone, CEO of the CRM platform Practifi. 'Advisors need to recognize where the personal connection is most powerful, and use AI to automate and alleviate the lesser functions.' READ ALSO: What the GENIUS Act Means for Stablecoins and Advisors and Why UBS Is the Only Wirehouse to Allow Podcasting Today, most advisors use AI to boost meeting efficiency and streamline workflows. Ideally, this frees up more time to spend with clients, but misusing these tools can backfire. 'The common refrain of disaffected clients is: 'I pay you to understand me, my goals, and my fears, not to outsource me to a machine,'' Johnstone said. Wealth management is built on bespoke service, but AI hasn't yet learned to fully adapt to individual client needs and goals. While tools that draft emails and website content are improving, the output still reads 'hollow and generic,' Johnstone warned. Use it or Lose it. Client-facing AI tools can be 'extremely risky' because they can't interpret emotional undertones of client's concerns, said Rafael Loureiro, CEO of an estate planning platform. Still, AI can be useful for quick, factual tasks. 'If it's midnight on a Sunday and a client asks, 'What was my marginal tax rate last year?' that's a perfect use case,' Loureiro said. 'It's not doing financial planning, but answering factual questions.' Everything in Moderation. This isn't the first time new tech or strategies meant to disrupt the wealth management industry have wound up causing trouble for advisors and their clients. Will Trout, director at Datos Insights, pointed to the 2008 financial crisis as a warning. 'Firms that over-relied on risk models without human oversight suffered catastrophic losses,' he told Advisor Upside. This post first appeared on The Daily Upside. To receive financial advisor news, market insights, and practice management essentials, subscribe to our free Advisor Upside newsletter. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
